Articles tagged with Small Cell Lung Cancer
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
A Phase III trial found stereotactic radiosurgery (SRS) improved overall survival in patients with small cell lung cancer (SCLC) brain metastases without significant difference in neurocognitive outcomes compared to hippocampal-avoidant whole brain radiotherapy (HA-WBRT).
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
A randomized trial found that brain MRI surveillance alone preserves cognitive function without a difference in survival, supporting MRI surveillance as the standard of care for patients with small cell lung cancer. No apparent difference was observed in overall survival and progression-free survival between the groups.
A metabolite called DAHB boosts immune cells against cancer, predicting tumor success and showing promise in small cell lung cancer treatment. Researchers also found that tumor CD19 levels can predict the success of CAR T cell therapy and identified a new targeted drug combination.
The investigational combination of pumitamig and elfetabart drozuntecan demonstrated encouraging early antitumor activity in patients with small cell lung cancer, with a 70.4% overall response rate. The combination also showed a manageable safety profile, supporting further clinical development.
A study from the University of Cologne identified a critical dependency in small cell lung cancer that can be exploited therapeutically. Targeted inhibition of the NMD pathway offers a promising approach to treat SCLC by accumulating mutated proteins and presenting abnormal peptides on the cell surface, making it detectable to the immu...
The NRG-LU005 trial found that patients receiving twice-daily radiation experienced a more favorable quality-of-life trajectory than those receiving once-daily radiation. This association remained after adjusting for patient characteristics, although the radiation schedule was not randomized.
Researchers found that adding a metabolite of vitamin B2 to bacteria in lung tumors increases the expression of a protein on immune cells, activating them to attack cancer. This discovery opens a new field of immunotherapy, targeting a previously underutilized immune cell type.
A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
Researchers developed a simple, fast, and low-cost blood test that identifies the tumor's biological fingerprint with over 90% accuracy. The test distinguishes between lung cancer patients and healthy individuals without DNA sequencing.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found significant sex-based protein differences in lung adenocarcinoma, with 901 proteins varying between male and female patient samples. This study contributes to understanding cancer biology and may benefit physicians and patients.
City of Hope's IMMUNO-BIOMAP trial aims to map how tumors change as they resist immunotherapy, focusing on non-small cell lung cancer. The six-year trial will use predictive models to identify groups of patients who respond well to personalized treatments.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
Researchers discovered lung cancer cells change identity to resist treatment by reactivating a process involved in early lung development. This could help doctors predict which patients respond well to treatment and provide personalized care.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
A new study found that diaphragmatic dome height on chest X-rays is a practical prognostic marker for predicting long-term outcomes and respiratory-related deaths in lung cancer patients with breathing disorders. Lower DDH before surgery was associated with poorer survival rates.
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Researchers found that inhibiting glucose transport can overcome tumor resistance to chloroquine treatment by inducing mitochondrial damage and oxidative stress. The study suggests a new combination therapy strategy for treating lung squamous cell carcinoma and subsets of adenocarcinoma with limited treatment options.
Breakthrough research recommends that more than one N1 node be removed and evaluated during surgery for non-small cell lung cancer (NSCLC). The study found that many cancers were identified in N1 nodes adjacent to the bronchi, highlighting the need for expanded lymph node evaluation.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Researchers identify a molecular target that enhances treatment for EGFR-mutant lung cancers prevalent in Asia. Disrupting this protective system can shrink tumors in laboratory models.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
ICIs combined with chemotherapy shows promise for treating EGFR-TKI-resistant NSCLC, improving PFS and OS. Acceptable safety profile for ICIs-chemotherapy regimen, suggesting potential as therapeutic option.
Cancer researchers at Cold Spring Harbor Laboratory have identified key proteins that determine the behavior of two hard-to-treat carcinomas, pancreatic cancer and tuft cell lung cancer. These findings could lead to new therapies targeting specific vulnerabilities in these cancers.
A population-based cohort study found that individuals following high-glycemic index diets had a 13% higher chance of developing lung cancer compared to those on low-GI diets. In contrast, those consuming high-glycemic load diets experienced a 28% lower risk of lung cancer.
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
The American Society for Radiation Oncology (ASTRO) has announced three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer Therapy Challenge. The selected projects aim to improve therapies and outcomes for patients with limited-stage SCLC through immunotherapy and radiation techniques.
A new study may transform the diagnosis of Britain's number one cancer, lung cancer. Researchers are investigating whether low-dose CT scans can detect lung cancers earlier than current chest X-rays. The study aims to identify which patients would benefit from these more accurate scans.
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
Researchers are collecting toenail clippings from Canadians to estimate a person's lung-cancer risk based on long-term radon exposure. The study aims to provide critical data for early screening and diagnosis of lung cancer.
A new grading system for invasive squamous cell carcinoma of the lung has been proposed based on tumor budding, with tumors classified as low-grade (0-9 buds/0.785 mm²) or high-grade (≥10 buds/0.785 mm²). The system was validated in a test set and demonstrated improved prognostic accuracy and guide treatment decisions.
A patient-reported outcomes analysis suggests that twice-daily radiation is associated with better quality of life and longer survival compared to once-daily radiation in patients with limited-stage small cell lung cancer. The study found less clinically meaningful decline in quality of life among those receiving twice-daily radiation.
Researchers identify basal stem-like cells as the origin of small cell lung cancer, providing a major shift in understanding this deadly disease. The study's findings allow for exploration of strategies to prevent the disease before it evades the immune system and spreads.
Researchers discover lung cancer cells in the brain form synapses with neurons, promoting tumor growth. This finding highlights the importance of neural signaling in cancer growth and suggests novel therapies to interrupt this signaling.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
Research presents IFITM3 as critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. Enhanced MHC-I expression improves antigen presentation and boosts CD8⁺ T cell infiltration.
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
The European Lung Cancer Congress 2025 will take place in Paris from March 26-29, featuring renowned experts discussing the latest research on lung cancer prevention, diagnosis, and treatment. The congress will also include award lectures and live streaming of the event.
Researchers found that aggressive lung cancer cells can generate their own electrical activity, building an independent network within the tumour. This property is distinct from most other cancer types and may drive the tumour's ability to grow and spread.
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A new subtype of small cell lung cancer has been identified that primarily affects younger people who have never smoked. The disease has distinct clinical and pathological features, and a unique molecular mechanism involving chromothripsis-mediated DNA damage.
A new study found that Hispanic non-small cell lung cancer patients in South Florida tend to be diagnosed at earlier stages than White patients, with a lower likelihood of advanced-stage diagnoses. This disparity disappears when examining ethnic subpopulations within the Hispanic population.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.